Obesity-related metabolic dysfunction, endothelium imbalance, chronic inflammation, immune dysregulation, and its comorbidities may all have a role in systemic inflammation, leading to the pulmonary fibrosis and cytokine storm, which leads to failure of lung function, which is a hallmark of severe SARS-CoV-2 infection. Obesity may also disrupt the function of mucociliary escalators and cooperation of epithelial cell’s motile cilia in the airway, limiting the clearance of the coronavirus that causes severe acute respiratory syndrome (SARS-CoV-2). Adipose tissues in obese patients have a greater number of proteases and receptors for SARS-CoV-2 admittance, proposing that they could serve as an accelerator and reservoir for this virus, boosting immunological response and systemic inflammation. Lastly, anti-inflammatory cytokines such as anti-IL-6 and the infusion of mesenchymal stem cells could be used as a modulation therapy of immunity to help COVID-19 patients. Obesity, on the other hand, is linked to the progress of COVID-19 through a variety of molecular pathways, and obese people are part of the SARS-CoV-2 susceptible individuals, necessitating more protective measures. Graphical Abstract ga1
【저자키워드】 SARS-CoV-2, Inflammation, pandemic, obesity, COPD, Chronic obstructive pulmonary disease, JAK, Janus kinase, ARDS, acute respiratory distress syndrome, BMI, Body mass index, CI, Confidence interval, ACE-2, Angiotensin-Converting Enzyme-2, SARS-COV-2, severe acute respiratory syndrome coronavirus-2, Ang II, Angiotensin II, IL-6, Interleukin-6, CVD, cardiovascular disease, RAAS, renin-angiotensin-aldosterone system, OR, Odds Ratio IMV: Intermittent Mandatory Ventilation, HFD, High-Fat Diet, ERV, Expiratory Reserve Volume, FRC, Functional Residual Capacity, IFNs, Interferons, EAT, Epicardial Adipose Tissue, Respiratory compliance,